{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-097700","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.549337+00:00","generated_at":"2026-05-15T17:42:34.132112+00:00","sec_items":["1.01","1.02","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jaguar Health postpones royalty payments, extends notes, terminates 48,211 warrants","bullets":["Royalty payment start postponed to July 1, 2026; Uptown amount reduced to $11,125,282.54, Streeterville to $12,428,782.20.","2021 Note maturity extended to July 1, 2026; Outstanding Balance reduced to $6,596,304.11.","2025 Note maturity extended to March 12, 2029; Outstanding Balance reduced to $7,048,021.86.","Warrants for 48,211 shares of common stock terminated via agreement with Uptown, Streeterville, and Iliad.","Napo granted Streeterville security interest in Lechlemer and TDPRV collateral to secure 2025 Note."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-097700","json":"https://secwatch.observer/filing/0001193125-26-097700.json","markdown":"https://secwatch.observer/filing/0001193125-26-097700.md","text":"https://secwatch.observer/filing/0001193125-26-097700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/0001193125-26-097700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/d89977d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:42:34.132112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1685d967ebb2b4bfd4b67ef7515a9700af45191b","claim":"Jaguar Health, Inc. amended 2025 Note Amendment with Streeterville Capital, LLC valued at $7,048,021.86 (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, the Company also entered into an amendment (the “2025 Note Amendment”) with Streeterville to the secured promissory note in the original principal amount of $10,810,000.00 (the “2025 Note”) issued by the Company to Streeterville on November 12, 2025 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/0001193125-26-097700-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$7,048,021.86"},{"label":"Effective","value":"2026-03-06"}]},{"claim_id":"1d393b52ee7dd11f3d02e6e909300e2f58680c21","claim":"Jaguar Health, Inc. amended 2021 Note Amendment No. 3 with Streeterville Capital, LLC valued at $6,596,304.11 (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note Amendment No. 3”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “2021 Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/0001193125-26-097700-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$6,596,304.11"},{"label":"Effective","value":"2026-03-06"}]},{"claim_id":"a14200c29fc3d1d656eaf8a5b996f9d8d82729be","claim":"Jaguar Health, Inc. terminated Warrant Termination Agreement with Uptown Capital, LLC, Streeterville Capital, LLC, Iliad Research and Trading, L.P. (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, the Company entered into a warrant termination agreement (the “Warrant Termination Agreement”) with Uptown, Streeterville, and Iliad Research and Trading, L.P. (“Iliad”; and together with Uptown and Streeterville, collectively the “Investors”), pursuant to which, warrants exercisable into an aggregate of 48,211 shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”) previously issued by the Company to the Investors would be terminated.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/0001193125-26-097700-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"Uptown Capital, LLC, Streeterville Capital, LLC, Iliad Research and Trading, L.P."},{"label":"Effective","value":"2026-03-06"}]},{"claim_id":"c2f0f14daabd26198760eeb387f458da5ffaecc9","claim":"Jaguar Health, Inc. amended Streeterville 2022 Royalty Interest Global Amendment No. 4 with Streeterville Capital, LLC valued at $12,428,782.20 (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, the Company also entered into an amendment (the “Streeterville 2022 Royalty Interest Global Amendment No. 4”) to the royalty interest in the original principal amount of $12 million, as amended (the “Streeterville 2022 Royalty Interest”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which, (i) the starting date for the Company to make the monthly Royalty Payment under the Streeterville 2022 Royalty Interest would be postponed from April 1, 2026 to July 1, 2026, and (ii) the Royalty Repayment Amount (as defined in the Streeterville 2022 Royalty Interest) would be reduced by ten percent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/0001193125-26-097700-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$12,428,782.20"},{"label":"Effective","value":"2026-03-06"}]},{"claim_id":"ece8b5c2fdefc9222e72d6742d7e9c5af9c5c272","claim":"Jaguar Health, Inc. amended Uptown 2020 Royalty Interest Global Amendment No. 4 with Uptown Capital, LLC valued at $11,125,282.54 (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, Jaguar Health, Inc. (the “Company”) entered into an amendment (the “Uptown 2020 Royalty Interest Global Amendment No. 4”) to the royalty interest in the original principal amount of $12 million, as amended (the “Uptown 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, pursuant to which, (i) the starting date for the Company to make the monthly Royalty Payment under the Uptown 2020 Royalty Interest would be postponed from April 1, 2026 to July 1, 2026, and (ii) the Royalty Repayment Amount (as defined in the Uptown 2020 Royalty Interest) would be reduced by ten percent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/0001193125-26-097700-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Uptown Capital, LLC"},{"label":"Value","value":"$11,125,282.54"},{"label":"Effective","value":"2026-03-06"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}